# A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

Study · id `cardio:ct-nct04880850` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04880850](<https://clinicaltrials.gov/study/NCT04880850>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04880850

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.

## Technical summary

Registry record NCT04880850. Randomized; no masking; primary purpose treatment. Start 2021-05-14 (actual); primary completion 2022-06-16 (actual). Results posted on 2025-07-02.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 582 participants (enrolled count; ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Started: 2021-05-14 (actual) (ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Primary completion: 2022-06-16 (actual) (ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Completion: 2022-06-16 (actual) (ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Results first posted: 2025-07-02 (ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Countries: United States; Belgium; India; Italy; Japan; Mexico; Netherlands; Romania; Russia (ClinicalTrials.gov record NCT04880850, source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04880850-2025-12-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Acronym: ONWARDS 4
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin icodec
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial (`cardio:pubmed-37156252`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f6293ecefa3dcbd7111c684053895c600f29aa548a462a469d4b1ec74a6205c3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
